Clinical Trials at the UPMC Liver Steatosis and Metabolic Wellness Program

At the UPMC Liver Steatosis Metabolic Wellness Program, our team closely monitors clinical trials.

The team includes:

• Doctors
• Nurses
• Research assistants
• Data analysts

If you're thinking about taking part in a clinical trial, it's important to:

• Discuss your health and review your records with your care team to decide eligibility.
• Ask your care team to help you discuss your decision with family members and caregivers.
• Remember that taking part in a research study is voluntary. You may choose — or someone on the clinical trial team may ask you — to cease participation at any time.

Featured Clinical Trails and Research on Metabolic Dysfunction-Associated Steatosis Liver Disease (MASLD)

Intercept: REGENERATE Study on the Safety and Efficacy of Obeticholic Acid for Nonalcoholic Steatohepatitis (NASH)

• A phase three, double blind, randomized, long-term, placebo-controlled, multicenter study.

Who can participate

People with biopsy-proven noncirrhotic NASH.

What we'll study

Study randomized investigational oral drug vs. placebo and protocol testing at no cost to participants.

How we'll conduct the study

Participants randomized to chance of study drug or placebo for 18 months. Then may continue with active study drug for all participants (no placebo after 18 months).

Length of the study

Up to six years.

Status

Actively enrolling.

Who to contact

Amy Roundtree Schmotzer, RN, at 412-802-8567 or schmotzerar@upmc.edu.

Gilead: A Study on the Safety, Tolerability, and Efficacy of GS-4997 Alone or in Combination with Simtuzumab (SIM) for NASH and Fibrosis Stages F2-F3

• A phase two, randomized, open label study.

Who can participate

People with biopsy-proven noncirrhotic NASH.

What we'll study

Study randomized investigational drug vs. placebo and protocol testing at no cost to participants.

How we'll conduct the study

Study participants taking medication for 24 weeks, then see them four weeks later for safety evaluation.

Status

Closed to accrual. Participants on follow up.

Who to contact

Amy Roundtree Schmotzer, RN, at 412-802-8567 or schmotzerar@upmc.edu.

Contact Us About MASLD Clinical Trials

For more information about clinical trials, please contact Amy Roundtree Schmotzer, RN, at 412-802-8567 or schmotzerar@upmc.edu.

To make an appointment for care, contact the UPMC Liver Steatosis and Metabolic Wellness Program at 412-647-1170.